The current studies at the Asthma Research Center are open for enrollment unless otherwise noted. The Asthma Research Center runs multiple studies and each study varies in duration and compensation is up to $1200 for your time and effort.
To see if you are eligible for any of our studies, please contact us at 617-732-8201 or via e-mail at ARC@bwh.harvard.edu or Click HERE to complete our survey and see if you qualify to participate.
Screening for Participation in Lung and Airways Studies to advance Health (SPLASH)
The purpose of the study is to identify subjects for participation in the current asthma research studies listed below and any future studies. The study visit involves gathering information about your asthma and related medical conditions. Participants will be compensated up to $110 for this visit. Payments will be made through a digital gift card. Participants will be given parking vouchers for the BWH garages.
Read More
iCARE (Improving the quality of Care for Asthma patients at Risk of Exacerbations)
The iCARE (Improving the quality of Care for Asthma patients at Risk of Exacerbations) study is working with doctors and asthma patients to study two different asthma treatments that have BOTH been shown to reduce asthma attacks. Each way uses approved asthma medicines that are commonly used to treat asthma. The goal of this study is to learn how these treatments work for different people.
If you join the study, you will have one visit with a study team member. This visit can be either in person or online. During this visit you will:
Answer questions about your asthma, asthma medicines and overall health
Sign a consent form
Be assigned by chance, like flipping a coin, to one of the two study treatment groups, called MART or PARTICS.
The study team will show you how to use the treatment you are assigned. Each month for 16 months, you will be sent a short survey about your asthma. You can do it online or by phone interview.
If you decide to join, you will get:
$50 for your first visit.
$20 for each survey you complete.
$100 for study-related expenses.
After you pick up or receive your study medicine, you will get an extra $50 after every 3 surveys you complete to help cover study-related expenses, such as your study medicine.
You or your insurance will continue to pay for all other asthma medicines, including maintenance inhalers. Your participation is greatly appreciated. You will help us improve asthma care for patients at risk of serious attacks.
Celldex CDX-622
CDX622-02 is a Phase I study for people with mild to moderate asthma sponsored by Celldex Therapeutics. This study will help researchers assess the safety and effects of a new investigational treatment called CDX-622. The study medication is a type of antibody that binds to two different types of proteins in the body that are implicated in causing asthma. This may help better regulate the immune system and may help with asthma symptoms.
Participants who are currently prescribed low or medium dose daily inhalers may be eligible for this study. All participants will receive one intravenous infusion of the study medication and will attend a total of 7 clinic visits over 16 weeks. Study visits will include blood draws, pulmonary function testing, sputum inductions, and visit questionnaires. All study related visits, tests, and study treatments will be of no cost to the participant. Compensation is up to $1200 and parking during study visits is covered by vouchers for the BWH garages.
ENVEDA
The ENV-294-211 Asthma Study is a Phase 2 clinical research study evaluating a new investigational medication for moderate-to-severe asthma. Researchers are testing whether this oral medication is safe and whether it may help control or prevent asthma symptoms. Participants will be randomly assigned, like flipping a coin, to receive either the investigational medication (ENV-294) or a placebo, administered as an oral tablet. A placebo is a pill that looks the same but contains no active medication. Each participant has an equal 50/50 chance of receiving either option. Neither you nor your study doctor will know which you are receiving.
Eligible individuals must currently be taking a steady dose of a daily asthma controller inhaler (such as Symbicort®, Advair®, Breo®, or Dulera®) for at least 2 months.
Active participation lasts approximately 17–20 weeks and includes up to seven in-person visits to check on you and how you are responding to the study treatment. Study procedures include breathing tests, sputum inductions, blood draws, questionnaires, and completion of at-home electronic diaries.
All study-related visits, tests, and medications will be provided at no cost. Participants may receive compensation of up to $2550 and will be provided with parking vouchers for BWH garages.
PULSEAIR (Closed to enrollment)
PulseAir is an interventional study looking at a new way to use rescue medications. It is comparing a combination inhaler containing two types of drugs that have been approved by the FDA: a rescue drug for immediate relief (Albuterol), and an inhaled corticosteroid (Fluticasone Propionate) to address the underlying lung inflammation that causes symptoms such as coughing, wheezing, and shortness of breath, to the individual components and a placebo inhaler.
This study will help us learn if the combination inhaler is more effective compared to usual ‘reliever’ medications in relieving increased asthma symptoms and potential asthma attacks. Participants will use their study medication 2 puffs at 4 times a day.
Participants will have 6 in-person clinic visits and 2 phone call visits over 8-10 weeks. Clinic visits will be 2-3 hours, with two visits that will be 8 hours. Study visits include blood draws, pulmonary function testing, visit questionnaires, and completing at home eDiaries. Total compensation is up to $1450. All study-related visits, tests, and study medication will be of no cost to the participants. Participants will be given parking vouchers for the BWH garages for each visit.
AMGEN
(Closed to enrollment)
The AMG 691 study is a Phase I study for mild to moderate asthmatics sponsored by Amgen. This study is assessing the safety of the investigational drug AMG 691 and is looking to see how the drug moves through and works in the body.
Participants will have one 2 night in-patient stay, 19 clinic visits over 46 weeks. Participants will receive three study drug injections over the course of the study. Study visits include blood draws, pulmonary function testing, visit questionnaires, and completing at home eDiaries. All study related visits, tests and study treatments will be of no cost to the participant. Compensation is up to $4900 and parking during study visits is covered by vouchers for the BWH garages.
IDEA
(Closed to enrollment)
This Phase 4 clinical research study is examining the FDA-approved drug Dupixent (Dupilimab) and biomarkers in people with moderate to severe asthma. The study aims to compare the effect that the study drug (Dupixent vs. placebo) has on asthma exacerbations. The study team is looking to understand if the underlying presence of these biomarkers in your blood might indicate a more positive response to the study drug when compared to people who do not have this biomarker present.
Participants should be prescribed Inhaled Corticosteroids (such as Flovent, Pulmicort, QVAR, Advair, or Symbicort).
Participants will have at least 9 visits over an 18-month period. The study will provide all participants with Dulera and study drug for them to self-administer at no cost. Participants will be compensated up to $870. Participants will be given parking vouchers for the BWH garages.
Read More
ARRIVAL
(Closed to enrollment)
This Phase 4 clinical research study is examining the FDA-approved drug Dupixent (Dupilimab) and biomarkers in people with moderate to severe asthma. The study aims to compare the effect that the study drug (Dupixent vs. placebo) has on asthma exacerbations. The study team is looking to understand if the underlying presence of these biomarkers in your blood might indicate a more positive response to the study drug when compared to people who do not have this biomarker present.
Participants should be prescribed Inhaled Corticosteroids (such as Flovent, Pulmicort, QVAR, Advair, or Symbicort).
Participants will have at least 9 visits over an 18-month period. The study will provide all participants with Dulera and study drug for them to self-administer at no cost. Participants will be compensated up to $870. Participants will be given parking vouchers for the BWH garages.
Read More
FLAIR
(Closed to enrollment)
The FLAIR study is investigating a new approach to rescue medications by comparing an Albuterol-only inhaler to a combination inhaler (Fluticasone Propionate and Albuterol). This study will help us learn if this combination inhaler reduces severe asthma attacks compared to standard ‘reliever’ medications. The findings from this study may lead to better treatment options and help other people with asthma in the future. This is a Phase III clinical study sponsored by TEVA Pharmaceuticals.
Participants will have a minimum study treatment period of 24 weeks but for some participants it may be longer. There will be 3 onsite morning visits within the first 6 weeks of the study. After this initial period, onsite morning visits will occur once every 12 weeks with 1 phone call every 4 weeks (between visits).
Participants can expect to complete daily e-diaries (a handheld electronic device) and measure their lung function using a peak flow meter (a small device that you blow air into). Study drug will be provided at no cost. Participants will be compensated up to $600 for their participation. Participants will be given parking vouchers for the BWH garages.
AIRCULES
(Closed to enrollment)
The AIRCULES study is a clinical trial to assess the efficacy, safety, and tolerability of a new add-on therapy in moderate to severe asthma that is not well controlled. By choosing to volunteer for this study, you can help us learn if this new injectable add-on therapy will lead to better asthma control in people with moderate to severe asthma. We are looking for people who take daily maintenance inhalers and have used prednisone (or a similar steroid medication) for symptoms of an asthma attack in the past year. The findings from this study may lead to better treatment options and help other people with asthma in the future. This is a Phase II clinical study sponsored by SANOFI.
Participants will receive an injection of either the investigational drug or a placebo. There will be 16 onsite visits over approximately 12 months. Participants will be asked to complete daily e-diaries (a handheld electronic device) and measure their lung function using a peak flow meter (a small device that you blow air into). The study sponsor will cover copays for approved asthma medications taken by study participants for the duration of the trial. Compensation for participation is up to $2400 and parking during study visits is covered by vouchers for the BWH garages.
AIRPHRODITE
The Airphrodite study is an open label extension study of the AIRCULES study sponsored by SANOFI. This study is only open to participants that completed the AIRCULES study. All participants in the study will receive the investigational drug. There will be 26 onsite visits over 22months. Compensation is up to $3900.
Severe Asthma Research Program (SARP)
(Closed to enrollment)
In recent years scientists have learned more about the way mild-to-moderate
asthma works and the reasons people get it. However, scientists are still trying to figure out what makes severe asthma different and how they can do better to treat the disease.
One reason the study of severe asthma is difficult is that there are not as many people with severe asthma. In fact they make up less than 10% of people with
asthma. The Severe Asthma Research Program or SARP is a national research program created so that scientists in many locations across the country can run a single, important study, and together find enough volunteers with severe asthma to participate.
The Severe Asthma Research Program (SARP) at the BWH in Boston is lookingfor adults taking inhaled corticosteroids who have been told they have asthma bya doctor. The observational study involves coming to our research center 4-5
times over the course of about 3 years. Participants will take their usual asthma medications throughout, and, as with all our studies, compensation for time spent in our center is provided.
Read More